菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Newsletter: December 2019

WuXi Vaccines to Build a $240 Million Manufacturing Facility in Ireland

 

 

WuXi Biologic’ subsidiary WuXi Vaccines, engaged in human vaccine Contract Development & Manufacturing Organization (CDMO) business, will invest $240 million to build a new vaccine manufacturing facility in Ireland. This investment follows the 20-year manufacturing Letter of Intent signed by WuXi Vaccines earlier this year. Read More


Partner News

 

Biologic Products DNA to IND Timeline in 9 Months – Yes It Can Be Done! Read More

 

WuXi Biologics Congratulates Tychan for Dosing First Patient of a Zika Antibody after Record 9 Months of Development Read More

 

WuXi Biologics Congratulates Tychan on First-in-Class Monoclonal Antibody for Yellow Fever after Record 7 Months of Development Read More


Antibody Drug Conjugate / Bioconjugates

 

Antibody Drug Conjugate (ADC) Development and Manufacturing Challenges & Solutions Read More

 

WuXi Biologics to Expand Integrated Biologics Conjugation Solution Center to Include Commercial Manufacturing Read More


WuXiBody™ Bispecific Antibody News

 

New Flexible Bispecific Antibody Format Demonstrates Improved Therapeutic Properties And Manufacturability Read More

 

WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel Bispecific Antibody Immunotherapeutics Read More

 

I-Mab Biopharma Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Three Bispecific Antibody Programs Read More


WuXiUP™ Platform News

 

Is Continuous Biomanufacturing a Good Fit for Your Process? Read More

 

WuXi Biologics Achieves Breakthrough Titer of 51g/L in Cell Culture Productivity Read More


Resources

 

From Concept to Market – Unique approaches in Biomanufacturing (Webinar)

 

Advanced Process Development Using Automated Micro Bioreactors Shortens Timelines & Provides Process Solutions for a Rapid Scale Up (Webinar)

 

Scale-Out Plus Single-Use Can Multiply Yields (Article)

 

Capacity Strategies: The Strategies Behind Choosing Between Large-Scale and Single-Use Investments (Article)

 

Viral Safety in Biomanufacturing (Video)

 

Ask the Expert Continuous Manufacturing (Article)

 

Scale-Out vs. Scale-Up GMP Manufacturing (Article)

 

WuXi Biologics Publications (Archive)

 

WuXi Biologics Perspectives (Archive)


Awards and Achievements

 

WuXi Biologics wins 2019 CMO Leadership Awards in all six core categories Read More

 

WuXi Biologics receives “Asia’s Best CMO of 2018” award from IMAPAC Read More

 

WuXi Biologics standardizes a remarkable 12 month “DNA to IND” timeline through its streamlined development platform Read More